

Table S1. Subgroup analysis for primary outcome.

	Number of participants (number of studies)	Estimate SMD (95. CI; p-value; I ²)	Test of heterogeneity
Duration of follow-up			
< 6 months	171 (9)	-0.16 (-0.28 to -0.04; p = 0.008; I ² = 0%)	0.53
>6 months	189 (4)	-0.29 (-0.69 to 0.11; p = 0.15; I ² = 91%)	
Male participants			
< 22%	180 (6)	-0.10 (-0.23 to 0.04; p = 0.16; I ² = 0%)	0.19
>22%	159 (6)	-0.31 (-0.61 to -0.02; p = 0.04; I ² = 84%)	
Prolactin			
Low	388 (7)	-0.09 (-0.16 to 0.06; p = 0.35; I ² = 0%)	0.04
High	332 (6)	-0.33 (-0.58 to -0.09; p = 0.008; I ² = 72%)	
Macroprolactinoma			
≤ 30 %	118 (6)	-0.11 (-0.25 to 0.04; p = 0.14; I ² = 0%)	0.63
> 30 %	183 (5)	-0.34 (-0.69 to 0.01; p = 0.22; I ² = 87%)	
Random error			
Prospective	227 (9)	-0.26 (-0.44 to -0.07; p = 0.006; I ² = 70%)	0.27
Retrospective	133 (4)	-0.09 (-0.32 to 0.15; p = 0.47; I ² = 64%)	
Risk of bias			
Less	140 (5)	-0.30 (-0.56 to -0.05; p = 0.02; I ² = 70%)	0.31
High	220 (8)	-0.14 (-0.32 to 0.04; p = 0.12; I ² = 62%)	